Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

L.A. McKeown

October 09, 2025

News Daily News

Valve Thrombosis in TTVR Not Uncommon: Meta-analysis

Caitlin E. Cox

June 17, 2025

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

Michael O'Riordan

October 01, 2021

News Daily News

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

Michael O'Riordan

April 23, 2021

News Daily News

Aspirin Alone After TAVR Supported by Meta-analysis

Todd Neale

September 29, 2020

News Daily News

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

Michael O'Riordan

August 13, 2020

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Todd Neale

July 29, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2017

Shelley Wood

July 03, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Daily News

TAVR后阿司匹林单药疗法的疗效不比DAPT差，可能更安全

May 14, 2015

News Daily News

Post-TAVR Aspirin Monotherapy No Less Effective, Possibly Safer Than DAPT

May 14, 2015

News Daily News

La Monoterapia con Aspirina Post-TAVR No es Menos Eficaz y es Posiblemente Más Segura que el Tratamiento Antiplaquetario Doble

May 14, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

Cilostazol Reduces Repeat Revascularizations for Long Lesions

March 06, 2011

Advertisement

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

Valve Thrombosis in TTVR Not Uncommon: Meta-analysis

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

Aspirin Alone After TAVR Supported by Meta-analysis

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

TCTMD’s Top 10 Most Popular Stories for June 2017

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

TAVR后阿司匹林单药疗法的疗效不比DAPT差，可能更安全

Post-TAVR Aspirin Monotherapy No Less Effective, Possibly Safer Than DAPT

La Monoterapia con Aspirina Post-TAVR No es Menos Eficaz y es Posiblemente Más Segura que el Tratamiento Antiplaquetario Doble

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

Cilostazol Reduces Repeat Revascularizations for Long Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content